ArticleHepatology (Baltimore, Md.)2011
Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings.
Article in Hepatology (Baltimore, Md.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 610 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
610 citing papers in PubMed, 1,211 citations in OpenAlex.
- HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study.Clinical and molecular hepatology · 2025Trial
- Trial
- Shorter leukocyte telomere length protects against NAFLD progression in children.Scientific reports · 2023Trial
- Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis.Journal of hepatology · 2023Trial
- Deciphering the relational dynamics of AF-2 domain of PAN PPAR through drug repurposing and comparative simulations.PloS one · 2023Trial
- Transcriptomic trajectory of hepatocyte ballooning reveals a lipotoxic point of no return and initiates oncogenic regulatory rewiring in MASLD.Biochemistry and biophysics reports · 2026Article
- Incidence of Cardiovascular Events and Extrahepatic Malignancies in Steatotic Liver Disease Subgroups.Digestive diseases and sciences · 2026Article
- Lauric-acid-rich Hermetia illucens meal modulates lipid metabolism in the liver and the fatty acid profile in piglet tissues.Scientific reports · 2026Article
- The monoacylglycerol acyltransferase 2 inhibitor VB-85387 reduces MASLD.Journal of lipid research · 2026Article
- Noninvasive Detection of MASH and Fibrotic Burden Using Ultrasound-Derived LIID and LSM in MASLD: A Multicenter Study.Journal of gastroenterology and hepatology · 2026Article
- Hepatic stellate cell subpopulations in human MASLD-related hepatocellular carcinoma upregulate YAP via geranylgeranyl pyrophosphate.Hepatology communications · 2026Article
- Hepatocyte RAP1A Deletion Impairs Lipid Catabolism and Worsens Steatosis via Autophagy Activation.Diabetes & metabolism journal · 2026Article
- Vertical Sleeve Gastrectomy Versus Comprehensive Lifestyle Intervention for Adolescents With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Controlled Cohort Study.Alimentary pharmacology & therapeutics · 2026Article
- European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) steatotic liver disease special interest group position paper on screening, diagnosis and investigation of paediatric metabolic dysfunction-associated steatotic liver disease.Journal of pediatric gastroenterology and nutrition · 2026Article
- Hepatic LGALS4 Alleviates Diet-Induced Steatosis by Promoting AMPK-Dependent Fatty Acid Oxidation.Diabetes, obesity & metabolism · 2026Article
- Vitexin-loaded phytosomes protect against high-fat diet-induced MASLD modulating PI3K/AKT/mTOR/SREBP-1c, Nrf2/HO-1, NF-κB/COX-2, and apoptotic pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- SIRPα Cleavage Is Associated with Inflammatory Response, Corticosteroid Nonresponse, and Worse Prognosis in Clinical and Preclinical Models of Alcohol-Associated Hepatitis.The American journal of pathology · 2026Article
- Magnesium isoglycyrrhizinate alleviates alcohol-associated liver disease through targeting HSD11B1.eLife · 2026Article
- Bovine Milk-Derived Extracellular Vesicles Ameliorate Steatohepatitis by Restoring Gut Barrier in CDA-HFD-Fed Mice.International journal of molecular sciences · 2026Article
- Effect of heat stress and GlyNAC supplementation on jejunal morphology, hepatic inflammation infiltration and distribution of GSH content in chickens.Poultry science · 2026Article
550 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
unlabelledThe diagnosis of nonalcoholic steatohepatitis (NASH) is defined by the presence and pattern of specific histological abnormalities on liver biopsy. A separate system of scoring the features of nonalcoholic fatty liver disease (NAFLD) called the NAFLD Activity Score (NAS) was developed as a tool to measure changes in NAFLD during therapeutic trials. However, some studies have used threshold values of the NAS, specifically NAS ≥5, as a surrogate for the histologic diagnosis of NASH. To evaluate whether this unintended use of the NAS is valid, biopsy and clinical data from the 976 adults in NASH Clinical Research Network (CRN) studies were reviewed. Biopsies were evaluated centrally by the NASH CRN Pathology Committee. Definite steatohepatitis (SH) was diagnosed in 58.1%, borderline SH in 19.5% and "not SH" in 22%. The NAS was ≥5 in 50% and ≤4 in 49%; in this cohort only 75% of biopsies with definite SH had an NAS ≥5, whereas 28% of borderline SH and 7% of "not SH" biopsies had NAS ≥5. Of biopsies with an NAS ≥5, 86% had SH and 3% "not SH". NAS ≤4 did not indicate benign histology; 29% had SH and only 42% had "not SH." Higher values of the NAS were associated with higher levels of alanine aminotransferase and aspartate aminotransferase, whereas the diagnosis of SH was associated with features of the metabolic syndrome.
conclusionThe diagnosis of definite SH or the absence of SH based on evaluation of patterns as well as individual lesions on liver biopsies does not always correlate with threshold values of the semiquantitative NAS. Clinical trials and observational studies should take these different performance characteristics into account.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.